1 Product identity
Ingredient risk
1 ingredient to use with caution
Serrapeptase
BrandDr. LaMar's Products→Non-Nutrient/Non-Botanical Tablet or Pill 7 ingredients 1 caution DSLD #180433Net contents: 120 Enteric Coated Tablet(s)
Target: Adults and Children 4 years and above
DSLD entry: 2018-09-21
2 Ingredients (7)
IngredientGroupSafety
SerratiopeptidaseSerratiopeptidase—
Microcrystalline CelluloseCellulose—
Stearic AcidStearic Acid—
Enteric CoatingCoating—
Ingredient amounts require the full DSLD label. View full label at NIH DSLD →
⚠️ Use with caution — restricted in some markets
Magnesium — Severe deficiency (<0.50 mmol/L) causes secondary hypocalcemia and hypokalemia that will not correct until magnesium is repleted first [1].
3 Safety cross-reference
Calcium — Conditionally Safe
⚠ Cardiovascular risk debated >1,000 mg/day
⚠ Kidney stones
Magnesium — Use with Caution
⚠ Diarrhea (especially oxide)
⚠ Accumulates in renal impairment
Sodium — Limited Evidence
⚠ Hypertension
⚠ Fluid retention
4 Label claims
• All Other
• Structure/Function
5 Data source
DSLD ID180433
Full labelView at NIH DSLD →
SourceOffice of Dietary Supplements, NIH
Market statusOn market
Entry date2018-09-21
6 More from Dr. LaMar's Products
View Dr. LaMar's Products Safety Scorecard → 7 products
Arginol FusionFiberAideLiquid BentoniteLiver Support WasabiaOmega3Pure Coconut Oil7 Cite this page
Vancouver
Pkhakadze G. Serrapeptase — product analysis [Internet]. Tbilisi: Public Health Institute of Georgia; 2026 [cited 2026 Oct 21]. Available from: https://supplement.ge/products/dsld-180433/
CC BY 4.0. Product data from NIH DSLD; safety analysis by SupplementIndex.
GP
Analyzed by SupplementIndex
PHIG · Editor-in-Chief: Prof. Giorgi Pkhakadze, MD, MPH, PhD
Product data sourced from the NIH Dietary Supplement Label Database (DSLD). Safety cross-referencing by SupplementIndex. This analysis is for informational purposes only. For corrections: info@accreditation.ge.
Publisher: PHIG
Publisher: PHIG